Subcutaneous formulation of lecanemab in Japan approved. Expanded at-home administration options are expected to improve treatment flexibility, with only a minor impact on the earnings guidance for the 2027 fiscal year.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4523","jir_company_name":"Eisai Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-09-16","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/09\/4523-20260916-01.pdf","jir_short_summary":"Subcutaneous formulation of lecanemab in Japan approved. Expanded at-home administration options are expected to improve treatment flexibility, with only a minor impact on the earnings guidance for the 2027 fiscal year.","jir_summary":"### Overview of the News\nEisai announced that the subcutaneous formulation of the anti-amyloid beta protofibril antibody 'Leqembi\u00ae'\u2014the subcutaneous injection 'Leqembi\u00ae subcutaneous 250 mg pen'\u2014has been approved in Japan as a new route of administration. Subcutaneous dosing is once weekly, two pens (total 500 mg), enabling home administration, which is expected to shorten administration time and reduce medical resource use compared with IV administration.\n\n### Scope and Future Prospects\nThe approval targets early AD (MCI and mild dementia), and home self-administration will be possible after post-approval review and acceptance for insurance coverage. Data demonstrating equivalent efficacy and safety to IV administration is cited as the basis, and treatment pathway efficiency is expected.","jir_financial_highlights":"Impact on 2027 FY earnings guidance: Unknown (Unknown)","jir_category":"","jir_hashtags":"#Eisai, #NotificationofApproval","jir_key_figures":"Unknown: Revenue, operating income, net income, etc. (financial metrics)\nUnknown: Concrete figures for cost savings from home administration implementation\nUnknown: Amounts and YoY changes in 2027 FY earnings guidance","jir_meta_title":"\u3010Eisai\u3011Lecanemab subcutaneous 250 mg pen approval in Japan \/ Expanded at-home administration options","jir_meta_description":"Japan-approved subcutaneous formulation of Leqembi (lecanemab) from Eisai and Biogen. Introduction of at-home administration once a week is expected to reduce clinic visits, with limited impact on earnings in FY2027 explained.","jir_og_title":"\u3010Eisai\u3011Lecanemab subcutaneous injection 250 mg pen approval | Expanded at-home treatment options","jir_og_description":"First subcutaneous formulation of lecanemab approved in Japan. Home administration added, improving treatment convenience. Earnings impact for FY2027 is expected to be minor.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":7482,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"dividend","footnotes":""},"sector":[],"importance":[],"class_list":["post-114433","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n